Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2024-12-16 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including changes in management (CEO) and adjustments to the number of shares granted due to employee departures. This falls under the category of regulatory filings regarding capital structure and equity-based compensation, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like DIRS (Director's Dealing) or SHA (Share Issue) perfectly, and is a formal regulatory disclosure.
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is an amendment (정정신고) to a previous filing. It details changes to stock option grants, including the number of shares and the list of recipients. In the context of Korean corporate filings (DART system), this type of disclosure regarding stock options and capital-related changes falls under general regulatory filings when a more specific category like 'Director's Dealing' or 'Share Issue' does not perfectly align with the nature of the corporate action (which is an internal grant of options rather than a market transaction). Given the options provided, 'RNS' (Regulatory Filings) is the most appropriate fallback category for this type of corporate disclosure.
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) of a previous filing. It details changes to stock option grants, including the number of shares and the list of recipients. In the context of financial filings, reports regarding stock options, equity compensation, and capital changes that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as Regulatory Filings (RNS).
2024-12-16 Korean
[기재정정]주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically an amendment ('정정신고') to a previous filing. It details changes to the number of stock options granted, the list of recipients, and the responsible personnel. In the context of financial filings, reports regarding stock option grants, especially those involving amendments to capital-related instruments, are classified as Regulatory Filings (RNS) when they do not fit into more specific categories like 'Director's Dealing' or 'Share Issue'.
2024-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. This document details changes in share ownership by major shareholders and their special relations, including specific transaction dates, share counts, and reasons for changes (such as litigation resolution and addition of special relations). This type of filing is classified as a Major Shareholding Notification (MRQ) in the provided schema.
2024-11-04 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for SCM Lifescience Co., Ltd. (에스씨엠생명과학 주식회사) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, management discussions, and shareholding status, which is characteristic of a comprehensive interim financial report. It is not an announcement of a report (RPA) nor a simple certification (RNS). 9M 2024
2024-10-31 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.